

STERIS plc  
Consolidated Condensed Statements of Operations  
(Unaudited - In millions, except per share data)

	Three Months Ended March 31,		Twelve Months Ended March 31,	
	2026	2025	2026	2025
<b>Revenues</b>	\$ 1,588.4	\$ 1,480.5	\$ 5,935.9	\$ 5,459.5
<b>Cost of revenues</b>	891.3	839.3	3,309.4	3,056.8
<b>Gross profit</b>	697.1	641.2	2,626.5	2,402.8
<b>Operating expenses:</b>				
Selling, general, and administrative	351.8	333.9	1,407.7	1,334.3
Research and development	28.8	27.7	112.9	107.6
Illinois EO litigation settlement	—	48.2	—	48.2
Restructuring (credit) expense	(0.3)	15.3	4.1	46.0
<b>Total operating expenses</b>	380.3	425.1	1,524.7	1,536.1
<b>Income from operations</b>	316.8	216.1	1,101.8	866.6
<b>Non-operating expenses, net</b>				
Interest expense	15.1	17.1	60.7	86.3
Interest and miscellaneous income	(3.3)	(3.5)	(9.8)	(8.4)
Other expense (income), net	0.5	5.3	3.5	(7.4)
<b>Total non-operating expenses, net</b>	12.3	18.8	54.4	70.4
<b>Income from continuing operations before income tax expense</b>	304.5	197.3	1,047.3	796.2
<b>Income tax expense</b>	84.2	50.5	262.2	184.7
<b>Income from continuing operations, net of income tax</b>	\$ 220.4	\$ 146.9	\$ 785.1	\$ 611.6
<b>(Loss) income from discontinued operations, net of income tax</b>	\$ —	\$ (0.8)	\$ —	\$ 4.5
<b>Net income</b>	\$ 220.4	\$ 146.1	\$ 785.1	\$ 616.1
<b>Less: Net income attributable to noncontrolling interests</b>	0.1	0.4	2.8	1.4
<b>Net income attributable to shareholders</b>	\$ 220.3	\$ 145.7	\$ 782.3	\$ 614.6
<b>Net income from continuing operations attributable to shareholders</b>	\$ 220.3	\$ 146.5	\$ 782.3	\$ 610.1
<b>Earnings per ordinary share (EPS) - Basic</b>				
Continuing Operations	\$ 2.25	\$ 1.49	\$ 7.97	\$ 6.19
Discontinued Operations	\$ —	\$ (0.01)	\$ —	\$ 0.05
Total	\$ 2.25	\$ 1.48	\$ 7.97	\$ 6.24
<b>Earnings per ordinary share (EPS) - Diluted</b>				
Continuing Operations	\$ 2.24	\$ 1.48	\$ 7.93	\$ 6.16
Discontinued Operations	\$ —	\$ (0.01)	\$ —	\$ 0.05
Total	\$ 2.24	\$ 1.48	\$ 7.93	\$ 6.20
<b>Cash dividends declared per ordinary share outstanding</b>	\$ 0.63	\$ 0.57	\$ 2.46	\$ 2.23
<b>Weighted average number of shares outstanding used in EPS computation:</b>				
Basic number of shares outstanding	98.0	98.3	98.2	98.6
Diluted number of shares outstanding	98.4	98.8	98.7	99.1

**STERIS plc**  
**Consolidated Condensed Balance Sheets**  
(Unaudited - In millions)

	March 31, 2026	March 31, 2025
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 439.6	\$ 171.7
Accounts receivable, net	1,092.8	1,044.0
Inventories, net	631.8	581.3
Prepaid expenses and other current assets	230.4	203.8
<b>Total current assets</b>	<b>2,394.6</b>	<b>2,000.8</b>
Property, plant, and equipment, net	2,161.2	1,956.5
Lease right-of-use assets, net	155.2	156.4
Goodwill	4,194.8	4,095.7
Intangibles, net	1,620.0	1,854.4
Other assets	211.4	83.0
<b>Total assets</b>	<b>\$ 10,737.2</b>	<b>\$ 10,146.8</b>
<b>Liabilities and equity</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 338.8	\$ 280.8
Short-term indebtedness	118.9	125.0
Other current liabilities	687.4	616.4
<b>Total current liabilities</b>	<b>1,145.0</b>	<b>1,022.2</b>
Long-term indebtedness	1,812.8	1,918.7
Other liabilities	582.1	590.2
<b>Total equity</b>	<b>7,197.2</b>	<b>6,615.8</b>
<b>Total liabilities and equity</b>	<b>\$ 10,737.2</b>	<b>\$ 10,146.8</b>

## STERIS plc

### Segment Data

(Unaudited - In millions)

Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment's gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments.

	Three Months Ended March 31,		Twelve Months Ended March 31,	
	2026	2025	2026	2025
<b>Revenues:</b>				
Healthcare	\$ 1,136.3	\$ 1,057.2	\$ 4,208.6	\$ 3,878.7
AST	289.2	273.9	1,138.5	1,038.6
Life Sciences	162.9	149.5	588.8	542.3
<b>Total revenues</b>	<b>\$ 1,588.4</b>	<b>\$ 1,480.5</b>	<b>\$ 5,935.9</b>	<b>\$ 5,459.5</b>
<b>Income (loss) from operations before adjustments:</b>				
Healthcare	\$ 283.2	\$ 279.7	\$ 1,036.4	\$ 971.5
AST	131.1	122.2	524.7	465.6
Life Sciences	70.6	65.0	251.0	229.4
Corporate	(100.0)	(99.3)	(430.1)	(399.0)
<b>Total income from operations before adjustments</b>	<b>\$ 384.9</b>	<b>\$ 367.6</b>	<b>\$ 1,381.9</b>	<b>\$ 1,267.5</b>
<b>Less: Adjustments</b>				
Amortization of acquired intangible assets	\$ 65.4	\$ 70.9	\$ 265.0	\$ 273.8
Acquisition and integration related charges	1.1	1.9	6.2	11.2
Tax restructuring costs	—	—	0.5	0.1
Amortization of inventory and property "step up" to fair value	1.1	1.3	5.0	5.4
Restructuring charges	0.4	29.2	3.4	62.3
Illinois EO litigation settlement	—	48.2	—	48.2
<b>Income from operations</b>	<b>\$ 316.8</b>	<b>\$ 216.1</b>	<b>\$ 1,101.8</b>	<b>\$ 866.6</b>

**STERIS plc**  
**Consolidated Condensed Statements of Cash Flows**  
**(Unaudited - In millions)**

	<b>Twelve Months Ended March 31,</b>	
	<b>2026</b>	<b>2025</b>
<b>Operating activities:</b>		
Net income	\$ 785.1	\$ 616.1
Non-cash items	529.1	465.5
Changes in operating assets and liabilities	27.2	66.5
<b>Net cash provided by operating activities</b>	<b>1,341.4</b>	<b>1,148.1</b>
<b>Investing activities:</b>		
Purchases of property, plant, equipment, and intangibles	(369.0)	(370.1)
Proceeds from the sale of property, plant, equipment, and intangibles	10.5	9.2
Proceeds from the sale of businesses	—	814.6
Purchases of investments	(134.0)	(10.8)
Acquisition of businesses, net of cash acquired	(20.1)	(54.1)
<b>Net cash (used in) provided by investing activities</b>	<b>(512.5)</b>	<b>388.8</b>
<b>Financing activities:</b>		
Payments on term loans	—	(638.1)
Payments on Private Placement Senior Notes	(125.0)	(80.0)
Proceeds (payments) under credit facilities, net	3.0	(446.3)
Deferred financing fees and debt issuance costs	—	(2.3)
Acquisition related deferred or contingent consideration	(0.4)	(0.4)
Repurchases of ordinary shares	(235.5)	(211.3)
Cash dividends paid to ordinary shareholders	(241.8)	(219.9)
Distributions to noncontrolling interest	(1.4)	(2.1)
Contributions from noncontrolling interest	—	2.5
Stock option and other equity transactions, net	32.9	25.5
<b>Net cash used in financing activities</b>	<b>(568.2)</b>	<b>(1,572.4)</b>
Effect of exchange rate changes on cash and cash equivalents	7.2	0.2
Increase (decrease) in cash and cash equivalents	267.9	(35.3)
Cash and cash equivalents at beginning of period	171.7	207.0
Cash and cash equivalents at end of period	<b>\$ 439.6</b>	<b>\$ 171.7</b>

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares. STERIS's calculation of free cash flows may vary from other companies.

	<b>Twelve Months Ended March 31,</b>	
	<b>2026</b>	<b>2025</b>
<b>Calculation of Free Cash Flow:</b>		
Cash flows from operating activities	\$ 1,341.4	\$ 1,148.1
Purchases of property, plant, equipment, and intangibles	(369.0)	(370.1)
Proceeds from the sale of property, plant, equipment, and intangibles	10.5	9.2
<b>Free Cash Flow</b>	<b>\$ 982.9</b>	<b>\$ 787.2</b>

**STERIS plc**  
**Non-GAAP Financial Measures**  
(Unaudited - In millions, except per share data)

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

Management and the Board of Directors believe that the presentation of these non-GAAP financial measures, when considered along with our U.S. GAAP financial measures and the reconciliation to the corresponding U.S. GAAP financial measures, provides the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

To measure the percentage organic revenue growth, the Company removes the impact of acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.

**Three months ended March 31,**

	As reported, U.S. GAAP		Impact of Acquisitions		Impact of Divestitures		Impact of Foreign Currency Movements	U.S. GAAP Growth	Organic Growth	Constant Currency Organic Growth
	2026	2025	2026	2025	2026	2025	2026	2026	2026	2026
<b>Segment revenues:</b>										
Healthcare	\$ 1,136.3	\$ 1,057.2	\$ 2.4	\$ —	\$ 16.3		7.5 %	7.2 %	5.7 %	
AST	289.2	273.9	—	—	11.1		5.6 %	5.6 %	1.6 %	
Life Sciences	162.9	149.5	—	—	4.2		9.0 %	9.0 %	6.2 %	
<b>Total</b>	<b>\$ 1,588.4</b>	<b>\$ 1,480.5</b>	<b>\$ 2.4</b>	<b>\$ —</b>	<b>\$ 31.5</b>		<b>7.3 %</b>	<b>7.1 %</b>	<b>5.0 %</b>	

**Twelve months ended March 31,**

	As reported, U.S. GAAP		Impact of Acquisitions		Impact of Divestitures		Impact of Foreign Currency Movements	U.S. GAAP Growth	Organic Growth	Constant Currency Organic Growth
	2026	2025	2026	2025	2026	2025	2026	2026	2026	2026
<b>Segment revenues:</b>										
Healthcare	\$ 4,208.6	\$ 3,878.7	\$ 2.4	\$ —	\$ 33.5		8.5 %	8.4 %	7.6 %	
AST	1,138.5	1,038.6	—	—	30.8		9.6 %	9.6 %	6.7 %	
Life Sciences	588.8	542.3	—	—	10.1		8.6 %	8.6 %	6.7 %	
<b>Total</b>	<b>\$ 5,935.9</b>	<b>\$ 5,459.5</b>	<b>\$ 2.4</b>	<b>\$ —</b>	<b>\$ 74.4</b>		<b>8.7 %</b>	<b>8.7 %</b>	<b>7.3 %</b>	

STERIS plc  
**Non-GAAP Financial Measures (Continued)**  
(Unaudited - In millions, except per share data)

	Three months ended March 31,															
	Continuing Operations								(Loss) income from discontinued operations, net of income tax	Net income (loss) attributable to shareholders	Diluted EPS from continuing operations		Diluted EPS from discontinued operations		Diluted EPS <sup>(3)</sup>	
	Gross Profit		Income from Operations		Income from continuing operations, net of income tax						2026	2025	2026	2025	2026	2025
	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025
<b>As reported, U.S. GAAP</b>	<b>\$ 697.1</b>	<b>\$ 641.2</b>	<b>\$ 316.8</b>	<b>\$ 216.1</b>	<b>\$ 220.4</b>	<b>\$ 146.9</b>	<b>\$ —</b>	<b>\$ (0.8)</b>	<b>\$ 220.3</b>	<b>\$ 145.7</b>	<b>\$ 2.24</b>	<b>\$ 1.48</b>	<b>\$ —</b>	<b>\$ (0.01)</b>	<b>\$ 2.24</b>	<b>\$ 1.48</b>
Adjustments:																
Amortization of acquired intangible assets	1.2	1.0	65.4	70.9												
Acquisition and integration related charges	—	—	1.1	1.9												
Tax restructuring benefits	—	—	—	—												
Amortization of inventory and property "step up" to fair value	0.5	0.5	1.1	1.3												
Restructuring charges	0.7	13.8	0.4	29.2												
Illinois EO litigation settlement	—	—	—	48.2												
Other expense, net <sup>(1)</sup>					0.5	5.3										
Net impact of adjustments after tax <sup>(2)</sup>					57.6	118.6	—	0.8	58.1	124.7						
Net EPS impact											0.59	1.26	—	0.01	0.59	1.26
<b>Adjusted</b>	<b>\$ 699.6</b>	<b>\$ 656.5</b>	<b>\$ 384.9</b>	<b>\$ 367.6</b>	<b>\$ 278.4</b>	<b>\$ 270.7</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 278.3</b>	<b>\$ 270.3</b>	<b>\$ 2.83</b>	<b>\$ 2.74</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 2.83</b>	<b>\$ 2.74</b>

<sup>(1)</sup> Other expense, net includes various non-operating items primarily related to our investing activities.

<sup>(2)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments and a withholding tax cost incurred in connection with funding an equity-method investment.

<sup>(3)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.

STERIS plc  
Non-GAAP Financial Measures (Continued)  
(Unaudited - In millions, except per share data)

	Twelve months ended March 31,															
	Continuing Operations								Income (loss) from discontinued operations, net of income tax	Net income attributable to shareholders	Diluted EPS from continuing operations		Diluted EPS from discontinued operations		Diluted EPS <sup>(3)</sup>	
	Gross Profit		Income from Operations		Income from continuing operations, net of income tax											
	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025
<b>As reported, U.S. GAAP</b>	<b>\$ 2,626.5</b>	<b>\$ 2,402.8</b>	<b>\$ 1,101.8</b>	<b>\$ 866.6</b>	<b>\$ 785.1</b>	<b>\$ 611.6</b>	<b>\$ —</b>	<b>\$ 4.5</b>	<b>\$ 782.3</b>	<b>\$ 614.6</b>	<b>\$ 7.93</b>	<b>\$ 6.16</b>	<b>\$ —</b>	<b>\$ 0.05</b>	<b>\$ 7.93</b>	<b>\$ 6.20</b>
Adjustments:																
Amortization of acquired intangible assets	4.7	3.1	265.0	273.8												
Acquisition and integration related charges	0.1	1.6	6.2	11.2												
Tax restructuring costs	—	—	0.5	0.1												
Amortization of inventory and property "step up" to fair value	2.3	2.2	5.0	5.4												
Restructuring (credits) charges	(0.6)	16.2	3.4	62.3												
Illinois EO litigation settlement	—	—	—	48.2												
Other expense (income), net <sup>(1)</sup>					3.5	(7.4)										
Net impact of adjustments after tax <sup>(2)</sup>					217.6	310.5	—	6.6	221.1	309.7						
Net EPS impact											2.24	3.06		0.06	2.24	3.13
<b>Adjusted</b>	<b>\$ 2,633.0</b>	<b>\$ 2,426.0</b>	<b>\$ 1,381.9</b>	<b>\$ 1,267.5</b>	<b>\$ 1,006.2</b>	<b>\$ 914.7</b>	<b>\$ —</b>	<b>\$ 11.1</b>	<b>\$ 1,003.4</b>	<b>\$ 924.3</b>	<b>\$ 10.17</b>	<b>\$ 9.22</b>	<b>\$ —</b>	<b>\$ 0.11</b>	<b>\$ 10.17</b>	<b>\$ 9.33</b>

<sup>(1)</sup> Other expense (income), net includes various non-operating items primarily related to our investing activities.

<sup>(2)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments and a withholding tax cost incurred in connection with funding an equity-method investment.

<sup>(3)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.

STERIS plc  
Non-GAAP Financial Measures (Continued)  
(Unaudited - In millions, except per share data)

**FY 2027 Outlook**

**Twelve Months  
Ended March 31, 2027  
(Outlook)\***

Net income from continuing operations per diluted share	\$9.00 - \$9.20
Amortization of acquired intangible assets	2.08
Other unusual items	0.02
Adjusted net income from continuing operations per diluted share	<u>\$11.10 - \$11.30</u>
Cash flows from operating activities	\$1,225.0
Purchases of property, plant, equipment, and intangibles	<u>(375.0)</u>
Free Cash Flow	<u>\$850.0</u>

\* All amounts are estimates.

STERIS plc  
Unaudited Supplemental Financial Data  
Fourth Quarter Fiscal 2026  
For the Periods Ending March 31, 2026 and 2025

	FY 2026	FY 2025	FY 2026	FY 2025
	Q4	Q4	YTD	YTD
<b>Total Company Revenues - Continuing Operations</b>				
Consumables	\$ 458.2	\$ 430.0	\$ 1,808.4	\$ 1,685.9
Service	743.1	679.5	2,875.8	2,587.9
Total Recurring	\$ 1,201.3	\$ 1,109.5	\$ 4,684.2	\$ 4,273.8
Capital Equipment	\$ 387.1	\$ 371.1	\$ 1,251.7	\$ 1,185.7
<b>Total Revenues</b>	<b>\$ 1,588.4</b>	<b>\$ 1,480.5</b>	<b>\$ 5,935.9</b>	<b>\$ 5,459.5</b>
<b>Ireland Revenues</b>	<b>\$ 31.9</b>	<b>\$ 38.2</b>	<b>\$ 108.5</b>	<b>\$ 107.3</b>
Ireland Revenues as a % of Total	2 %	2 %	2 %	2 %
<b>United States Revenues</b>	<b>\$ 1,145.8</b>	<b>\$ 1,078.6</b>	<b>\$ 4,333.8</b>	<b>\$ 4,007.6</b>
United States Revenues as a % of Total	72 %	73 %	73 %	73 %
<b>International Revenues</b>	<b>\$ 410.7</b>	<b>\$ 363.7</b>	<b>\$ 1,493.7</b>	<b>\$ 1,344.6</b>
International Revenues as a % of Total	26 %	25 %	25 %	25 %

<b>Segment Data - Continuing Operations</b>	FY 2026	FY 2025	FY 2026	FY 2025
	Q4	Q4	YTD	YTD
<b>Healthcare</b>				
<b>Revenues</b>				
Consumables	\$ 376.4	\$ 352.7	\$ 1,496.6	\$ 1,396.0
Service	422.8	386.4	1,616.0	1,445.4
Total Recurring	\$ 799.1	\$ 739.2	\$ 3,112.6	\$ 2,841.5
Capital Equipment	337.1	318.0	1,095.9	1,037.2
Total Healthcare Revenues	\$ 1,136.3	\$ 1,057.2	\$ 4,208.6	\$ 3,878.7
<b>Segment Operating Income</b>	<b>\$ 283.2</b>	<b>\$ 279.7</b>	<b>\$ 1,036.4</b>	<b>\$ 971.5</b>
<b>AST</b>				
<b>Revenues</b>				
Service	\$ 283.1	\$ 257.8	\$ 1,118.5	\$ 1,007.6
Capital Equipment	6.1	16.0	20.0	30.9
Total AST Revenues	\$ 289.2	\$ 273.9	\$ 1,138.5	\$ 1,038.6
<b>Segment Operating Income</b>	<b>\$ 131.1</b>	<b>\$ 122.2</b>	<b>\$ 524.7</b>	<b>\$ 465.6</b>
<b>Life Sciences</b>				
<b>Revenues</b>				
Consumables	\$ 79.9	\$ 76.0	\$ 308.3	\$ 286.7
Service	39.2	36.4	144.8	138.1
Total Recurring	\$ 119.1	\$ 112.5	\$ 453.1	\$ 424.7
Capital Equipment	43.9	37.0	135.7	117.5
Total Life Sciences Revenues	\$ 162.9	\$ 149.5	\$ 588.8	\$ 542.3
<b>Segment Operating Income</b>	<b>\$ 70.6</b>	<b>\$ 65.0</b>	<b>\$ 251.0</b>	<b>\$ 229.4</b>
<b>Corporate Operating Loss</b>	<b>\$ (100.0)</b>	<b>\$ (99.3)</b>	<b>\$ (430.1)</b>	<b>\$ (399.0)</b>

<b>Other Data</b>	FY 2026	FY 2025	FY 2026	FY 2025
	Q4	Q4	YTD	YTD
Healthcare Backlog	\$ 392.1	\$ 369.2		
Life Sciences Backlog	98.7	83.7		
<b>Total Backlog - Continuing Operations</b>	<b>\$ 490.7</b>	<b>\$ 452.9</b>		
<b>As reported, U.S. GAAP Income Tax Rate - Continuing Operations</b>	<b>27.6 %</b>	<b>25.6 %</b>	<b>25.0 %</b>	<b>23.2 %</b>
<b>Adjusted Income Tax Rate - Continuing Operations</b>	<b>25.4 %</b>	<b>23.5 %</b>	<b>24.4 %</b>	<b>23.1 %</b>
<b>As reported, U.S. GAAP Income Tax Rate - Discontinued Operations</b>	<b>— %</b>	<b>86.4 %</b>	<b>— %</b>	<b>(371.0)%</b>
<b>Adjusted Income Tax Rate - Discontinued Operations</b>	<b>— %</b>	<b>26.9 %</b>	<b>— %</b>	<b>26.9 %</b>

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.